KALA BIO, Inc. (NASDAQ:KALA) CFO Mary Reumuth Sells 1,706 Shares

KALA BIO, Inc. (NASDAQ:KALA) CFO Mary Reumuth sold 1,706 shares of KALA BIO stock in a transaction on Monday, January 6th. The shares were sold at an average price of $7.63, for a total transaction of $13,016.78. Following the transaction, the chief financial officer now owns 68,581 shares in the company, valued at $523,273.03. The trade was a 2.43 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

KALA BIO Stock Up 2.1 %

NASDAQ KALA traded up $0.16 during mid-day trading on Tuesday, reaching $7.69. 45,377 shares of the company’s stock traded hands, compared to its average volume of 105,019. The company has a fifty day simple moving average of $6.71 and a 200-day simple moving average of $6.32. KALA BIO, Inc. has a 1-year low of $4.21 and a 1-year high of $9.25. The company has a market cap of $35.45 million, a price-to-earnings ratio of -0.62 and a beta of -2.11. The company has a current ratio of 2.15, a quick ratio of 2.15 and a debt-to-equity ratio of 3.18.

KALA BIO (NASDAQ:KALA) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($1.93) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.43) by $0.50. As a group, equities research analysts expect that KALA BIO, Inc. will post -10.84 EPS for the current year.

Institutional Investors Weigh In On KALA BIO

A hedge fund recently bought a new stake in KALA BIO stock. SR One Capital Management LP acquired a new stake in shares of KALA BIO, Inc. (NASDAQ:KALA) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 443,661 shares of the company’s stock, valued at approximately $3,146,000. KALA BIO accounts for about 1.0% of SR One Capital Management LP’s investment portfolio, making the stock its 9th biggest holding. SR One Capital Management LP owned approximately 15.76% of KALA BIO at the end of the most recent reporting period. 24.61% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and set a $15.00 price objective on shares of KALA BIO in a research note on Friday, November 15th.

About KALA BIO

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.